Zealand Pharma A/S

Zealand Pharma A/S Q3 2026 Earnings Recap

ZEAL.CO Q3 2026 Published November 14, 2026

Get alerts when ZEAL.CO reports next quarter

Set up alerts — free

Shares fell 1.3% after the update, a relatively flat reaction. The transcript highlighted pipeline and partnership progress, including positive petrelintide data, but did not provide financial results or updated guidance to assess against expectations.

Earnings Per Share Beat
$-0.80 vs $-10.58 est.
+92.4% surprise
Revenue Miss
4074853 vs 8821429 est.
-53.8% surprise

Market Reaction

Post-Earnings -1.26%

See ZEAL.CO alongside your other holdings

Add to your portfolio — free

Key Takeaways

  • In the 220-participant ZUPREME-2 trial, petrelintide produced up to 9.2% mean weight loss at week 28; HbA1c fell by up to 0.65 percentage points, versus a 0.23% increase on placebo.
  • GI-related discontinuations in ZUPREME-2 were 1.9% on petrelintide and 1.7% on placebo. In the earlier ZUPREME-1 trial, mean weight loss reached 10.7% at week 42.
  • Zealand said Roche and Zealand launched a global registrational phase III program for petrelintide. Boehringer Ingelheim plans a global regulatory submission for survodutide in obesity in 2027 and is adding phase III trials.
  • Glepaglutide received a positive CHMP opinion in Europe for short bowel syndrome; Zealand also reported positive results for ZP9830, which moved into phase I-B for plaque psoriasis.
  • Management cited more than $2 billion on the balance sheet and outlined investment in its Cambridge research hub and a Generate Biomedicines collaboration.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ZEAL.CO on AllInvestView.

Get the Full Picture on ZEAL.CO

Track Zealand Pharma A/S in your portfolio with real-time analytics, dividend tracking, and more.

View ZEAL.CO Analysis